ArticleMolecular cancer2009
Targeting EGFR with photodynamic therapy in combination with Erbitux enhances in vivo bladder tumor response.
Article in Molecular cancer, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 60 citations in OpenAlex.
- A Nano-Isolation Strategy for Tumor-Activatable Photodynamic Therapy via Aggregation-Gated Type I Photosensitizers.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Shedding Light on Chemoresistance: The Perspective of Photodynamic Therapy in Cancer Management.International journal of molecular sciences · 2024Review
- RNA-seq reveals novel mechanistic targets of Livin in bladder cancer.BMC urology · 2023Article
- Advances in Management of Bladder Cancer-The Role of Photodynamic Therapy.Molecules (Basel, Switzerland) · 2022Review
- EGF Conjugation Improves Safety and Uptake Efficacy of Titanium Dioxide Nanoparticles.Molecules (Basel, Switzerland) · 2020Article
- Endoscopic Molecular Imaging plus Photoimmunotherapy: A New Strategy for Monitoring and Treatment of Bladder Cancer.Molecular therapy oncolytics · 2020Review
- Photoimmunotherapy of Ovarian Cancer: A Unique Niche in the Management of Advanced Disease.Cancers · 2019Review
- Modeling Epidermal Growth Factor Inhibitor-mediated Enhancement of Photodynamic Therapy Efficacy Using 3D Mesothelioma Cell Culture.Photochemistry and photobiology · 2019Article
- Functional Polymer Nanocarriers for Photodynamic Therapy.Pharmaceuticals (Basel, Switzerland) · 2018Review
- Preclinical investigation of folate receptor-targeted nanoparticles for photodynamic therapy of malignant pleural mesothelioma.International journal of oncology · 2018Article
- Chemophototherapy: An Emerging Treatment Option for Solid Tumors.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2017Review
- Fluence Rate Differences in Photodynamic Therapy Efficacy and Activation of Epidermal Growth Factor Receptor after Treatment of the Tumor-Involved Murine Thoracic Cavity.International journal of molecular sciences · 2016Article
- Targeted therapies in bladder cancer: an overview of in vivo research.Nature reviews. Urology · 2015Review
- Erlotinib Pretreatment Improves Photodynamic Therapy of Non-Small Cell Lung Carcinoma Xenografts via Multiple Mechanisms.Cancer research · 2015Article
- Nimotuzumab increases the anti-tumor effect of photodynamic therapy in an oral tumor model.Oncotarget · 2015Article
- Targeted PDT agent eradicates TrkC expressing tumors via photodynamic therapy (PDT).Molecular pharmaceutics · 2015Article
- Impact of ERBB2 mutations on in vitro sensitivity of bladder cancer to lapatinib.Cancer biology & therapy · 2014Article
- Carboplatin synergistically triggers the efficacy of photodynamic therapy via caspase 3-, 8-, and 12-dependent pathways in human anaplastic thyroid cancer cells.Lasers in medical science · 2014Article
- Restoration of LRIG1 suppresses bladder cancer cell growth by directly targeting EGFR activity.Journal of experimental & clinical cancer research : CR · 2013Article
- The effects of Photofrin-mediated photodynamic therapy on the modulation of EGFR in esophageal squamous cell carcinoma cells.Lasers in medical science · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPhotodynamic therapy (PDT) is a promising cancer treatment modality that involves the interaction of the photosensitizer, molecular oxygen and light of specific wavelength to destroy tumor cells. Treatment induced hypoxia is one of the main side effects of PDT and efforts are underway to optimize PDT protocols for improved efficacy. The aim of this study was to investigate the anti-tumor effects of PDT plus Erbitux, an angiogenesis inhibitor that targets epidermal growth factor receptor (EGFR), on human bladder cancer model. Tumor-bearing nude mice were assigned to four groups that included control, PDT, Erbitux and PDT plus Erbitux and tumor volume was charted over 90-day period.
resultsOur results demonstrate that combination of Erbitux with PDT strongly inhibits tumor growth in the bladder tumor xenograft model when compared to the other groups. Downregulation of EGFR was detected using immunohistochemistry, immunofluorescence and western blotting. Increased apoptosis was associated with tumor inhibition in the combination therapy group. In addition, we identified the dephosphorylation of ErbB4 at tyrosine 1284 site to play a major role in tumor inhibition. Also, at the RNA level downregulation of EGFR target genes cyclin D1 and c-myc was observed in tumors treated with PDT plus Erbitux.
conclusionThe combination therapy of PDT and Erbitux effectively inhibits tumor growth and is a promising therapeutic approach in the treatment of bladder tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.